Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment
Low-grade gliomas (LGGs) pose significant challenges in cancer research and treatment due to their infiltrative nature and tendency for recurrence, making them the most common brain tumour in adults. Most of the LGGs have the propensity to cause notable alterations in the microenvironment of the tu...
Saved in:
| Main Authors: | Hurais Malik, Muhammad Hudaib, Abdul Rehman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2024-09-01
|
| Series: | Journal of the Pakistan Medical Association |
| Subjects: | |
| Online Access: | https://jpma.org.pk/index.php/public_html/article/view/20428 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions
by: Zhenjiang Pan, et al.
Published: (2025-06-01) -
Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand
by: Meghana Maddula, et al.
Published: (2025-03-01) -
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma
by: Alexander S. Himstead, et al.
Published: (2025-01-01) -
Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
by: Bai Xuexue, et al.
Published: (2025-08-01) -
Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult
by: Michael Youssef, et al.
Published: (2025-09-01)